Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Thomas Lakin Creveling
Observed names:
Creveling, Thomas,
T., Creveling,
Thomas Creveling
Institution:
Eli Lilly (United States)
Observed institution:
Eli Lilly (United States)
OpenAlex ID:
A5093083084
Cost per remission for mirikizumab versus ustekinumab for moderately to severely active ulcerative colitis treatment from the United States commercial payer perspective
2025
·
Ankit Gulati
, Neha Mittal
, et al.
·
Journal of Medical Economics
·
2
PDF
Budget Impact of Mirikizumab-mrkz in the Treatment of Adult Patients With Moderately-to-severely Active Ulcerative Colitis in the United States
2024
·
Matthew Stargardter
, Navneet Upadhyay
, et al.
·
Inflammatory Bowel Diseases
·
2
PDF
Real-world Rate and Magnitude of Dose Escalation With Biologics in Patients With Crohn’s Disease
2024
·
Magdaliz Gorritz
, Rifat Tuly
, et al.
·
Inflammatory Bowel Diseases
·
2
PDF
Real-World Dose Escalation and Associated Direct Costs of Biologics in Management of Ulcerative Colitis: A Retrospective Database Study
2025
·
Miguel Regueiro
, Tania Gulati
, et al.
·
Digestive Diseases
·
1
Real-world Dosing Patterns of Biologics in Crohn’s Disease and Ulcerative Colitis: a Retrospective Observational Study
2025
·
Casey Chapman
, Aisha Vadhariya
, et al.
·
Inflammatory Bowel Diseases
·
1
Cost Per Remission for Mirikizumab Vs Ustekinumab in the Maintenance Phase for Moderately-to-severely Active Ulcerative Colitis Treatment From the United States Commercial Payer Perspective
2024
·
Ankit Gulati
, Sunanda Kane
, et al.
·
Inflammatory Bowel Diseases
·
1
PDF
S993 Treatment Persistence and Augmentation Differences Across Second-Line Treatment Strategies Among TNFi Experienced Ulcerative Colitis Patients: TNFi Cyclers vs MOA Switchers
2023
·
Magdaliz Gorritz
, Rifat Tuly
, et al.
·
The American Journal of Gastroenterology
·
1
Biologic dose escalation in inflammatory bowel disease in the United States
2026
·
Casey Chapman
, Aisha Vadhariya
, et al.
·
Journal of Managed Care & Specialty Pharmacy
Costs Per Response and Remission of Mirikizumab Vs Risankizumab in the Maintenance Phase for Moderately to Severely Active Crohn's Disease Treatment in the United States
2026
·
Meenakshi Bewtra
, Tommaso Panni
, et al.
·
Gastroenterology
Costs Per Response and Remission of Mirikizumab Vs Risankizumab in the Maintenance Phase for Moderately to Severely Active Crohn’s Disease Treatment in the United States
2026
·
Meenakshi Bewtra
, Tommaso Panni
, et al.
·
Inflammatory Bowel Diseases
Tu1864: REAL-WORLD DOSING PATTERNS OF BIOLOGICS IN CROHN’S DISEASE AND ULCERATIVE COLITIS: A RETROSPECTIVE OBSERVATIONAL STUDY
2025
·
Casey Chapman
, Aisha Vadhariya
, et al.
·
Gastroenterology
Real-world Dosing Patterns of Biologics in Crohn’s Disease and Ulcerative Colitis: a Retrospective Observational Study
2025
·
Casey Chapman
, Aisha Vadhariya
, et al.
·
Gastroenterology
Real-world Rate and Magnitude of Dose Escalation With Biologics in Patients With Ulcerative Colitis
2024
·
Magdaliz Gorritz
, Rifat Tuly
, et al.
·
Gastroenterology
Real-world Rate and Magnitude of Dose Escalation With Biologics in Patients With Crohn’s Disease
2024
·
Magdaliz Gorritz
, Rifat Tuly
, et al.
·
Gastroenterology
PDF
Cost Per Remission for Mirikizumab Vs Ustekinumab in the Maintenance Phase for Moderately-to-severely Active Ulcerative Colitis Treatment From the United States Commercial Payer Perspective
2024
·
Ankit Gulati
, Sunanda Kane
, et al.
·
Gastroenterology
PDF
Budget Impact of Mirikizumab-mrkz in the Treatment of Adult Patients With Moderately-to-severely Active Ulcerative Colitis in the United States
2024
·
Matthew Stargardter
, Navneet Upadhyay
, et al.
·
Gastroenterology
PDF
Real-world Rate and Magnitude of Dose Escalation With Biologics in Patients With Ulcerative Colitis
2024
·
Magdaliz Gorritz
, Rifat Tuly
, et al.
·
Inflammatory Bowel Diseases
PDF
Show more works
View as search
Works count:
19
Citation count:
10
H-index:
2
I10-index:
Year
Topic
Type
